Assay News and Research

RSS

At least 3 exposures to vaccine or virus needed for minimum protection against SARS-CoV-2 Omicron

Researchers determine the serum neutralizing and binding activity against the SARS-CoV-2 Omicron variant in individuals with different levels of immunity.

29 Dec 2021

COVID mRNA vaccines show diminished neutralization responses against Omicron

Researchers report an overview of antibody neutralization by all currently approved vaccines against the SARS-CoV-2 Omicron, Beta, and Delta VOCs.

29 Dec 2021

Exploring immunogenicity and safety after a homologous booster dose of SARS-CoV-2 recombinant spike protein vaccine

Research suggests that a single booster dose of NVX-CoV2373 given approximately six months after the primary series induced significant increases in humoral antibodies, while also exhibiting an acceptable safety profile.

29 Dec 2021

Booster dose of mRNA vaccines found crucial in protecting against SARS-CoV-2 Omicron variants

A new study shows that Omicron is more infectious than any of the other variants and that booster vaccines, especially mRNA vaccines, are capable of neutralizing Omicron variants of pseudoviruses.

29 Dec 2021

SARS-CoV-2 infection induces robust and cross-reactive immune responses in children

Researchers compare the convalescent humoral and cellular immune responses between children and adults infected with SARS-CoV-2.

28 Dec 2021

SARS-CoV-2 Omicron variant neutralized by third BNT162b2 booster shot

A new preprint* research paper under consideration at Nature Portfolio Journal assesses the susceptibility of the Omicron variant to neutralizing antibody response after booster immunization.

28 Dec 2021

Pre-existing immunity against influenza can lower SARS-CoV-2 infection burden and spread

A recent study by a team of European researchers demonstrated how antibodies induced by currently circulating influenza A H1N1 strains can cross-react with the important part of the SARS-CoV-2 spike glycoprotein that interacts with the human cell receptor. Their paper is currently available on the medRxiv* preprint server while it undergoes peer review.

28 Dec 2021

Study suggests spike mutation makes SARS-CoV-2 Omicron milder

The Omicron spike is relatively poorly cleaved and impaired in mediating cell-cell fusion and syncytia formation, contrary to predictions.

28 Dec 2021

Children with pre-existing immunity to common cold demonstrate better protection against COVID-19

New data shows that, compared to adults, children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) preferentially activate pre-existing acquired immunity to prevalent common cold coronaviruses that cross-react with SARS-CoV-2 and protect them from severe disease.

24 Dec 2021

Allele-specific RT-qPCR assay to identify SARS-CoV-2 Omicron variant in wastewater

Researchers develop a new allele-specific RT-qPCR to detect the SARS-CoV-2 Omicron variant in wastewater.

23 Dec 2021

Researchers report loss of antibody potency against SARS-CoV-2 Omicron variant

Researchers find that vaccine-mediated protection against SARS-CoV-2 is significantly reduced against the Omicron variant.

23 Dec 2021

Coinfection of SARS-CoV-2 and human rhinovirus associated with more severe health outcomes

Researchers discuss the incidence and effect of coinfections with SARS-CoV-2 and human rhinovirus.

23 Dec 2021

T-cell response to Omicron after an mRNA COVID vaccine booster

In a recent prospective observational study posted to the medRxiv* preprint server, researchers determined Omicron variant-associated T cell responses before and after a third dose of messenger ribonucleic acid (mRNA) vaccination against coronavirus disease (COVID-19) in anti-CD20-treated multiple sclerosis (MS) patients.

22 Dec 2021

Assay News and Research

At least 3 exposures to vaccine or virus needed for minimum protection against SARS-CoV-2 Omicron

COVID mRNA vaccines show diminished neutralization responses against Omicron

Exploring immunogenicity and safety after a homologous booster dose of SARS-CoV-2 recombinant spike protein vaccine

Booster dose of mRNA vaccines found crucial in protecting against SARS-CoV-2 Omicron variants

SARS-CoV-2 infection induces robust and cross-reactive immune responses in children

SARS-CoV-2 Omicron variant neutralized by third BNT162b2 booster shot

Pre-existing immunity against influenza can lower SARS-CoV-2 infection burden and spread

Study suggests spike mutation makes SARS-CoV-2 Omicron milder

Children with pre-existing immunity to common cold demonstrate better protection against COVID-19

Allele-specific RT-qPCR assay to identify SARS-CoV-2 Omicron variant in wastewater

Researchers report loss of antibody potency against SARS-CoV-2 Omicron variant

Coinfection of SARS-CoV-2 and human rhinovirus associated with more severe health outcomes

T-cell response to Omicron after an mRNA COVID vaccine booster

Role of novel SARS-CoV-2-derived svRNAs and the involvement of tRF in COVID-19

Extended interval between second and third vaccination beneficial against SARS-CoV-2 Omicron variant

Study suggests nitazoxanide fails to reduce the severity of SARS-CoV-2

Scientists identify a panel of nanobodies with good neutralizing efficacy against SARS-CoV-2 variants of concern

Comparison of SARS-CoV-2 rapid antigen tests

Comparison of point-of-care SARS-CoV-2 diagnostic kits

Diagnostic assays that use the 2019-nCoV-N1 primer-probe are unlikely to be impacted by Omicron variant

eBook: Using iPSCs models for human disease research and drug discovery eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News